Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456430 · ClinicalTrials.gov registry record · Phase 4
Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT00456430 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 80 participants.
The verdict
NCT00456430, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients.In particular, this study will investigate whether variation in the serotonin transporter gene can affect the response to escitalopram as measured by clinical interview and MRI scan. We will measure activity in different parts of the brain, while subjects see pictures, using Magnetic Resonance Imaging (MRI) scan. There will be three MRI scans; one before we start any medication, one during the study after 3 weeks of treatment and one after six more weeks of treatment. Treatment will consist of Escitalopram. Additionally a blood sample will be taken for genetic testing. The genetic samples collected are to look at variation in a gene (serotonin transporter gene), which affects the functioning of the chemical serotonin in the brain.
Interventions
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2003-07 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00456430
The ClinicalTrials.gov registry entry for NCT00456430 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Escitalopram is the first listed.
NCT00456430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00456430 about?
NCT00456430 is a clinical study titled "Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response". The purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients.In particular, this study will investigate whether variation in the serotonin transporter gene c...
What is the current status of trial NCT00456430?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2003-07. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00456430?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00456430?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.